当前位置: 首页 >> 检索结果
461. Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial.
作者: Maria Cecilia Bahit.;Ralph L Sacco.;J Donald Easton.;Juliane Meyerhoff.;Lisa Cronin.;Eva Kleine.;Claudia Grauer.;Martina Brueckmann.;Hans-Christoph Diener.;Renato D Lopes.;Michael Brainin.;Phillippe Lyrer.;Rolf Wachter.;Tomas Segura.;Christopher B Granger.; .
来源: Circulation. 2021年144卷22期1738-1746页
A proportion of patients with embolic stroke of undetermined source have silent atrial fibrillation (AF) or develop AF after the initial evaluation. Better understanding of the risk for development of AF is critical to implement optimal monitoring strategies with the goal of preventing recurrent stroke attributable to underlying AF. The RE-SPECT ESUS trial (Randomized, Double-Blind Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source) provides an opportunity to assess predictors for developing AF and associated recurrent stroke.
462. Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD.
作者: Connie N Hess.;E Sebastian Debus.;Mark R Nehler.;Sonia S Anand.;Manesh R Patel.;Michael Szarek.;Warren H Capell.;Judith Hsia.;Joshua A Beckman.;Marianne Brodmann.;Rafael Diaz.;Peter Habertheuer.;Nicholas J Leeper.;Richard J Powell.;Henrik Sillesen.;Eva Muehlhofer.;Scott D Berkowitz.;Lloyd P Haskell.;Rupert M Bauersachs.;Marc P Bonaca.
来源: Circulation. 2021年144卷23期1831-1841页
Patients with peripheral artery disease (PAD) are at heightened risk of acute limb ischemia (ALI), a thrombotic event associated with amputation, disability, and mortality. Previous lower extremity revascularization (LER) is associated with increased ALI risk in chronic PAD. However, the pattern of risk, clinical correlates, and outcomes after ALI early after LER are not well-studied, and effective therapies to reduce ALI post-LER are lacking.
463. Truncating Variants in OBSCN Gene Associated With Disease-Onset and Outcomes of Hypertrophic Cardiomyopathy.
作者: Guixin Wu.;Jie Liu.;Minghao Liu.;Qiya Huang.;Jieyun Ruan.;Channa Zhang.;Dong Wang.;Xiaolu Sun.;Wen Jiang.;Lianming Kang.;Jizheng Wang.;Lei Song.
来源: Circ Genom Precis Med. 2021年14卷5期e003401页
The presence of variants in OBSCN was identified to be linked to hypertrophic cardiomyopathy (HCM), but whether OBSCN truncating variants were associated with HCM remained unknown.
464. Rare, Damaging DNA Variants in CORIN and Risk of Coronary Artery Disease: Insights From Functional Genomics and Large-Scale Sequencing Analyses.
作者: Minxian Wang.;Vivian S Lee-Kim.;Deepak S Atri.;Nadine H Elowe.;John Yu.;Colin W Garvie.;Hong-Hee Won.;Joseph E Hadaya.;Bryan T MacDonald.;Kevin Trindade.;Olle Melander.;Daniel J Rader.;Pradeep Natarajan.;Sekar Kathiresan.;Virendar K Kaushik.;Amit V Khera.;Rajat M Gupta.
来源: Circ Genom Precis Med. 2021年14卷5期e003399页
Corin is a protease expressed in cardiomyocytes that plays a key role in salt handling and intravascular volume homeostasis via activation of natriuretic peptides. It is unknown if Corin loss-of-function (LOF) is causally associated with risk of coronary artery disease (CAD).
465. Epigenetic Age and the Risk of Incident Atrial Fibrillation.
作者: Jason D Roberts.;Eric Vittinghoff.;Ake T Lu.;Alvaro Alonso.;Biqi Wang.;Colleen M Sitlani.;Pedrum Mohammadi-Shemirani.;Myriam Fornage.;Jelena Kornej.;Jennifer A Brody.;Dan E Arking.;Honghuang Lin.;Susan R Heckbert.;Ivana Prokic.;Mohsen Ghanbari.;Allan C Skanes.;Traci M Bartz.;Marco V Perez.;Kent D Taylor.;Steven A Lubitz.;Patrick T Ellinor.;Kathryn L Lunetta.;James S Pankow.;Guillaume Paré.;Nona Sotoodehnia.;Emelia J Benjamin.;Steve Horvath.;Gregory M Marcus.
来源: Circulation. 2021年144卷24期1899-1911页
The most prominent risk factor for atrial fibrillation (AF) is chronological age; however, underlying mechanisms are unexplained. Algorithms using epigenetic modifications to the human genome effectively predict chronological age. Chronological and epigenetic predicted ages may diverge in a phenomenon referred to as epigenetic age acceleration (EAA), which may reflect accelerated biological aging. We sought to evaluate for associations between epigenetic age measures and incident AF.
466. A Novel Visually Guided Radiofrequency Balloon Ablation Catheter for Pulmonary Vein Isolation: One-Year Outcomes of the Multicenter AF-FICIENT I Trial.
作者: Vivek Y Reddy.;Amin Al-Ahmad.;Audrius Aidietis.;Matthew Daly.;Iain Melton.;Yan Hu.;Matthew Sulkin.;Gediminas Rackauskas.;Adrian Ebner.;Darren A Hooks.;Aamir Sofi.;Petr Neužil.;Ian G Crozier.
来源: Circ Arrhythm Electrophysiol. 2021年14卷10期e009308页
[Figure: see text].
467. Effects of Lifestyle Modification on Patients With Resistant Hypertension: Results of the TRIUMPH Randomized Clinical Trial.
作者: James A Blumenthal.;Alan L Hinderliter.;Patrick J Smith.;Stephanie Mabe.;Lana L Watkins.;Linda Craighead.;Krista Ingle.;Crystal Tyson.;Pao-Hwa Lin.;William E Kraus.;Lawrence Liao.;Andrew Sherwood.
来源: Circulation. 2021年144卷15期1212-1226页
Although lifestyle modifications generally are effective in lowering blood pressure (BP) among patients with unmedicated hypertension and in those treated with 1 or 2 antihypertensive agents, the value of exercise and diet for lowering BP in patients with resistant hypertension is unknown.
468. One-Year Committed Exercise Training Reverses Abnormal Left Ventricular Myocardial Stiffness in Patients With Stage B Heart Failure With Preserved Ejection Fraction.
作者: Michinari Hieda.;Satyam Sarma.;Christopher M Hearon.;James P MacNamara.;Katrin A Dias.;Mitchel Samels.;Dean Palmer.;Sheryl Livingston.;Margot Morris.;Benjamin D Levine.
来源: Circulation. 2021年144卷12期934-946页
Individuals with left ventricular (LV) hypertrophy and elevated cardiac biomarkers in middle age are at increased risk for the development of heart failure with preserved ejection fraction. Prolonged exercise training reverses the LV stiffening associated with healthy but sedentary aging; however, whether it can also normalize LV myocardial stiffness in patients at high risk for heart failure with preserved ejection fraction is unknown. In a prospective, randomized controlled trial, we hypothesized that 1-year prolonged exercise training would reduce LV myocardial stiffness in patients with LV hypertrophy.
469. No-Touch Versus Conventional Vein Harvesting Techniques at 12 Months After Coronary Artery Bypass Grafting Surgery: Multicenter Randomized, Controlled Trial.
作者: Meice Tian.;Xianqiang Wang.;Hansong Sun.;Wei Feng.;Yunhu Song.;Feng Lu.;Liqing Wang.;Yang Wang.;Bo Xu.;Huaibin Wang.;Su Liu.;Zhigang Liu.;Yu Chen.;Qi Miao.;Pixiong Su.;Yan Yang.;Shaoxian Guo.;Bin Lu.;Zhiqiang Sun.;Kaiyang Liu.;Changwei Zhang.;Yue Wu.;Haitao Xu.;Wei Zhao.;Chao Han.;Xingtong Zhou.;Enshi Wang.;Xiaoning Huo.;Shengshou Hu.
来源: Circulation. 2021年144卷14期1120-1129页
Vein graft occlusion is deemed a major challenge in coronary artery bypass grafting. Previous studies implied that the no-touch technique for vein graft harvesting could reduce occlusion rate compared with the conventional approach; however, evidence on the clinical benefit and generalizability of the no-touch technique is scare.
470. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
作者: Kai-Ni Shen.;Wei-Jun Fu.;Yu Wu.;Yu-Jun Dong.;Zhong-Xia Huang.;Yong-Qiang Wei.;Chun-Rui Li.;Chun-Yan Sun.;Ye Chen.;Hui-Lei Miao.;Yue-Lun Zhang.;Xin-Xin Cao.;Dao-Bin Zhou.;Jian Li.
来源: Circulation. 2022年145卷1期8-17页
Doxycycline was demonstrated in a retrospective study to be associated with greater survival in patients with light chain amyloidosis. Therefore, we prospectively compared the efficacy of bortezomib-cyclophosphamide-dexamethasone (CyBorD) and CyBorD combined with doxycycline for cardiac light chain amyloidosis.
471. Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity.
作者: Harmony R Reynolds.;Leslee J Shaw.;James K Min.;Courtney B Page.;Daniel S Berman.;Bernard R Chaitman.;Michael H Picard.;Raymond Y Kwong.;Sean M O'Brien.;Zhen Huang.;Daniel B Mark.;Ranjit K Nath.;Sudhanshu K Dwivedi.;Paola E P Smanio.;Peter H Stone.;Claes Held.;Matyas Keltai.;Sripal Bangalore.;Jonathan D Newman.;John A Spertus.;Gregg W Stone.;David J Maron.;Judith S Hochman.
来源: Circulation. 2021年144卷13期1024-1038页
The ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) postulated that patients with stable coronary artery disease (CAD) and moderate or severe ischemia would benefit from revascularization. We investigated the relationship between severity of CAD and ischemia and trial outcomes, overall and by management strategy.
472. Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study.
作者: Matthias Thielmann.;David Corteville.;Gabor Szabo.;Madhav Swaminathan.;Andre Lamy.;Lukas J Lehner.;Craig D Brown.;Nicolas Noiseux.;Mohamed G Atta.;Elizabeth C Squiers.;Shai Erlich.;Daniel Rothenstein.;Bruce Molitoris.;C David Mazer.
来源: Circulation. 2021年144卷14期1133-1144页
Acute kidney injury (AKI) affects up to 30% of patients undergoing cardiac surgery, leading to increased in-hospital and long-term morbidity and mortality. Teprasiran is a novel small interfering RNA that temporarily inhibits p53-mediated cell death that underlies AKI.
473. Cryoballoon Versus High-Power, Short-Duration Radiofrequency Ablation for Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation: A Single-Center, Prospective, Randomized Study.
作者: Hui-Nam Pak.;Je-Wook Park.;Song-Yi Yang.;Tae-Hoon Kim.;Jae-Sun Uhm.;Boyoung Joung.;Moon-Hyoung Lee.;Hee Tae Yu.
来源: Circ Arrhythm Electrophysiol. 2021年14卷9期e010040页
[Figure: see text].
474. Predictive Accuracy of a Clinical and Genetic Risk Model for Atrial Fibrillation.
作者: Shaan Khurshid.;Nina Mars.;Christopher M Haggerty.;Qiuxi Huang.;Lu-Chen Weng.;Dustin N Hartzel.; .;Kathryn L Lunetta.;Jeffrey M Ashburner.;Christopher D Anderson.;Emelia J Benjamin.;Veikko Salomaa.;Patrick T Ellinor.;Brandon K Fornwalt.;Samuli Ripatti.;Ludovic Trinquart.;Steven A Lubitz.
来源: Circ Genom Precis Med. 2021年14卷5期e003355页
Atrial fibrillation (AF) risk estimation using clinical factors with or without genetic information may identify AF screening candidates more accurately than the guideline-based age threshold of ≥65 years.
475. Genotype-Phenotype Correlation of SCN5A Genotype in Patients With Brugada Syndrome and Arrhythmic Events: Insights From the SABRUS in 392 Probands.
作者: Anat Milman.;Elijah R Behr.;Belinda Gray.;David C Johnson.;Antoine Andorin.;Aviram Hochstadt.;Jean-Baptiste Gourraud.;Shingo Maeda.;Yoshihide Takahashi.;Jimmy Jm Juang.;Sung-Hwan Kim.;Tsukasa Kamakura.;Takeshi Aiba.;Pieter G Postema.;Yuka Mizusawa.;Isabelle Denjoy.;Carla Giustetto.;Giulio Conte.;Zhengrong Huang.;Georgia Sarquella-Brugada.;Andrea Mazzanti.;Camilla H Jespersen.;Elena Arbelo.;Ramon Brugada.;Leonardo Calo.;Domenico Corrado.;Ruben Casado-Arroyo.;Giuseppe Allocca.;Masahiko Takagi.;Pietro Delise.;Josep Brugada.;Jacob Tfelt-Hansen.;Silvia G Priori.;Christian Veltmann.;Gan-Xin Yan.;Pedro Brugada.;Fiorenzo Gaita.;Antoine Leenhardt.;Arthur A M Wilde.;Kengo F Kusano.;Gi-Byoung Nam.;Kenzo Hirao.;Vincent Probst.;Bernard Belhassen.
来源: Circ Genom Precis Med. 2021年14卷5期e003222页
Brugada syndrome (BrS) is associated with mutations in the cardiac sodium channel gene, SCN5A. However, genetic studies of patients with BrS with arrhythmic events have been limited. We sought to compare various clinical, ECG, and electrophysiological parameters according to SCN5A genotype in a large cohort of BrS probands with first arrhythmic event.
476. Contribution of Noncanonical Splice Variants to TTN Truncating Variant Cardiomyopathy.
作者: Parth N Patel.;Kaoru Ito.;Jon A L Willcox.;Alireza Haghighi.;Min Young Jang.;Joshua M Gorham.;Steven R DePalma.;Lien Lam.;Barbara McDonough.;Renee Johnson.;Neal K Lakdawala.;Amy Roberts.;Paul J R Barton.;Stuart A Cook.;Diane Fatkin.;Christine E Seidman.;J G Seidman.
来源: Circ Genom Precis Med. 2021年14卷5期e003389页
Heterozygous TTN truncating variants cause 10% to 20% of idiopathic dilated cardiomyopathy (DCM). Although variants which disrupt canonical splice signals (ie, invariant dinucleotide of the splice donor site, invariant dinucleotide of the splice acceptor site) at exon-intron junctions are readily recognized as TTN truncating variants, the effects of other nearby sequence variations on splicing and their contribution to disease is uncertain.
477. Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program.
作者: Barry H Trachtenberg.;Sachin K Shah.;Robert L Nussbaum.;Sara L Bristow.;Ruthvik Malladi.;Matteo Vatta.
来源: Circ Genom Precis Med. 2021年14卷5期e003466页 478. Utility of Genetically Predicted Lp(a) (Lipoprotein [a]) and ApoB Levels for Cardiovascular Risk Assessment.
作者: Haoyu Wu.;Jian'an Luan.;Vincenzo Forgetta.;James C Engert.;George Thanassoulis.;Vincent Mooser.;Nicholas J Wareham.;Claudia Langenberg.;J Brent Richards.
来源: Circ Genom Precis Med. 2021年14卷5期e003312页
Current lipid guidelines suggest measurement of Lp(a) (lipoprotein[a]) and ApoB (apolipoprotein B) for atherosclerotic cardiovascular disease risk assessment. Polygenic risk scores (PRSs) for Lp(a) and ApoB may identify individuals unlikely to have elevated Lp(a) or ApoB and thus reduce such suggested testing.
479. Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial.
作者: Dhanunjaya Lakkireddy.;David Thaler.;Christopher R Ellis.;Vijendra Swarup.;Lars Sondergaard.;John Carroll.;Michael R Gold.;James Hermiller.;Hans-Christoph Diener.;Boris Schmidt.;Lee MacDonald.;Moussa Mansour.;Brijeshwar Maini.;Laura O'Brien.;Stephan Windecker.
来源: Circulation. 2021年144卷19期1543-1552页
Percutaneous closure of the left atrial appendage (LAA) is an alternative to chronic oral anticoagulation to reduce stroke risk in patients with nonvalvular atrial fibrillation. The Amulet IDE trial (Amplatzer Amulet Left Atrial Appendage Occluder IDE Trial) was designed to evaluate the safety and effectiveness of the dual-seal mechanism of the Amulet LAA occluder compared with the Watchman device.
480. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
作者: Renato D Lopes.;Celestia S Higano.;Susan F Slovin.;Adam J Nelson.;Robert Bigelow.;Per S Sørensen.;Chiara Melloni.;Shaun G Goodman.;Christopher P Evans.;Jan Nilsson.;Deepak L Bhatt.;Noel W Clarke.;Tine K Olesen.;Belinda T Doyle-Olsen.;Henriette Kristensen.;Lauren Arney.;Matthew T Roe.;John H Alexander.; .
来源: Circulation. 2021年144卷16期1295-1307页
The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial.
|